New Lifetime High Reached: PTC Therapeutics (PTCT)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified PTC Therapeutics ( PTCT) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified PTC Therapeutics as such a stock due to the following factors:

  • PTCT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $13.7 million.
  • PTCT has traded 3,843 shares today.
  • PTCT is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in PTCT with the Ticky from Trade-Ideas. See the FREE profile for PTCT NOW at Trade-Ideas

More details on PTCT:

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. PTCT has a PE ratio of 1.4. Currently there are 5 analysts that rate PTC Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for PTC Therapeutics has been 285,500 shares per day over the past 30 days. PTC has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are up 113.4% year-to-date as of the close of trading on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates PTC Therapeutics as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share and deteriorating net income.

Highlights from the ratings report include:
  • Compared to its closing price of one year ago, PTCT's share price has jumped by 70.94%, exceeding the performance of the broader market during that same time frame. Although PTCT had significant growth over the past year, our hold rating indicates that we do not recommend additional investment in this stock at the current time.
  • PTCT has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 19.66, which clearly demonstrates the ability to cover short-term cash needs.
  • Compared to other companies in the Biotechnology industry and the overall market, PTC THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • PTC THERAPEUTICS INC's earnings per share declined by 38.7% in the most recent quarter compared to the same quarter a year ago. For the next year, the market is expecting a contraction of 131.7% in earnings (-$3.62 versus -$1.56).
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 72.1% when compared to the same quarter one year ago, falling from -$14.59 million to -$25.10 million.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Deutsche Bank Plans 'Significant' Job Cuts as Q1 Profits Slump

Deutsche Bank Plans 'Significant' Job Cuts as Q1 Profits Slump

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings